A clinician-level guide to metformin's approval history, current regulatory standing, and mechanism of action across the US, EU, Canada, and UK, with sourcing limitations flagged for editorial review.
A clinical guide to metformin use in patients with autoimmune conditions, covering the immunomodulatory mechanisms under study, disease-specific considerations, drug interactions, and monitoring, with a clear line drawn between FDA-approved use and investigational use.
A clinician-level review of how metformin affects bone mineral density, fracture risk, osteoblast activity, and osteoporosis outcomes in type 2 diabetes, with primary-literature citations throughout.
A clinician-level review of metformin's long-term cardiovascular effects, from UKPDS 34 through modern meta-analyses. Covers mechanisms, trial data, guideline positions, and practical prescribing context.
A clinician-level review of metformin's impact on cognitive function, covering mechanistic data, key trials, dosing considerations, and what current guidelines say about diabetes, aging, and brain health.
A physician-level breakdown of the metformin evidence base, with each major indication graded by GRADE certainty of evidence, key trial data, and practical clinical guidance.
A guide to metformin's effects on hair loss, skin pigmentation, acne, and wound healing. Covers B12-mediated hair thinning, androgen-driven skin benefits in PCOS, and practical monitoring thresholds backed by primary literature.
How metformin alters mitochondrial function, AMPK signaling, and hepatic glucose output, and what that means (and does not mean) for energy expenditure and weight. Written for clinicians and informed patients, pending qualified medical review.
A clinician-level review of how metformin affects skeletal muscle, which patients face the greatest risk of lean-mass loss, and the evidence-based strategies to preserve muscle while staying on metformin therapy.
A guide to the metformin pre-surgery hold window, covering current ADA and AACE guidelines, contrast-dye rules, procedure-specific timing, and restart protocols with primary-literature citations throughout.
A citation-dense review of how metformin affects sexual function in men and women with type 2 diabetes, PCOS, and prediabetes. Covers testosterone, erectile dysfunction, libido, and clinical management strategies.
A clinician-facing guide to monitoring adolescents aged 12 to 17 who are exposed to MK-677 (ibutamoren): IGF-1 surveillance, glucose and metabolic monitoring, growth-plate assessment, mental-health screening, and when to stop, with an explicit map of what is established versus unproven in this age group.
MK-677 mimics ghrelin at GHS-R1a receptors, triggering GHRH release and steady 24-hour GH and IGF-1 elevation without disrupting natural pulsatility.
A guide to the MK-677 (ibutamoren) missed-dose protocol, covering pharmacokinetics, how to skip or double doses safely, and the clinical reasoning behind each decision.
MK-677 (ibutamoren) is taken orally, not injected. Learn how this GH secretagogue works, what the clinical trial data show, and what physicians actually monitor during use.
A guide to monitoring MK-677 (ibutamoren) use in young adults aged 18-29, covering IGF-1 tracking, insulin sensitivity, pituitary axis, fertility, and safety checkpoints, with an honest account of what the evidence does and does not establish.
A analysis of MK-677 (ibutamoren) and its effects on liver function, covering hepatotoxicity risk, ALT/AST changes, GH-IGF-1 signaling, and monitoring protocols based on primary literature.
A clinical review of how MK-677 (ibutamoren) affects mood, sleep, anxiety, and cognitive function, including trial data, mechanism of action, and what the current evidence does and does not support.
A deep dive into MK-677 (ibutamoren) muscle preservation strategies, covering mechanisms, trial data, dosing protocols, and safety considerations for clinicians and informed patients.
A clinician-level guide to safely restarting MK-677 (ibutamoren) after acute illness, covering timing, dose re-titration, lab monitoring, contraindications, and the latest clinical evidence.
A guide to MK-677 rebound effects after stopping ibutamoren, covering GH/IGF-1 suppression, hunger spikes, fluid loss, and evidence-based tapering strategies.
A guide to MOTS-c dosing for adults aged 30 to 49, covering injection protocols, timing, metabolic targets, safety signals, and what the current trial evidence supports.
A guide to MOTS-c mitochondrial peptide safety in adults aged 30 to 49, covering known adverse effects, dosing data, and what human trial evidence does and does not yet support.
A source-led MOTS-c review for adults 50 to 64, distinguishing age-related human measurements, mouse treatment findings, and missing human safety data.
A clinician-level review of MOTS-c mitochondrial peptide safety signals, FDA enforcement actions, compounding restrictions, and what the current preclinical and human data actually say about risk.
A source-led MOTS-c safety review for adults 18 to 29, separating endogenous human measurements from administered-peptide evidence.
A clinician-level review of how the mitochondrial peptide MOTS-c affects appetite, food cravings, and satiety signaling, with primary-literature citations and dosing context for telehealth practice.
A comparison of compounded and branded MOTS-c peptide formulations, covering pharmacology, purity standards, dosing protocols, regulatory status, and clinical evidence from primary literature.
A clinician-level review of MOTS-c mitochondrial peptide after bariatric surgery, covering mechanisms, dosing considerations, metabolic rationale, and the current evidence gap in post-bariatric populations.
A clinician-level review of MOTS-c mitochondrial peptide and the kidneys: mechanistic data, animal studies, human signals, dosing considerations, and when renal monitoring is warranted.
A guide to MOTS-c dosing strategies for long-haul travel, circadian disruption, and timezone-shift recovery, with primary-literature citations and practical timing frameworks.
A guide to tirzepatide (Mounjaro) safety for adults ages 18, 29, covering trial data, hormonal effects, fertility, dosing, and monitoring protocols.
A clinical deep-dive into tirzepatide's long-term cardiovascular effects, covering SURPASS-CVOT, SURMOUNT-OSA, lipid changes, blood-pressure data, and what board-certified physicians need to know before prescribing.
A breakdown of compounded tirzepatide vs branded Mounjaro: efficacy data, safety differences, regulatory status, cost, and how to choose.
Stopping Mounjaro (tirzepatide) often triggers weight regain, rising blood sugar, and appetite resurgence. Learn what the evidence says, how fast rebound occurs, and what clinicians recommend to minimize it.
A deep dive into how tirzepatide (Mounjaro) affects sexual function in men and women, covering hormonal mechanisms, clinical trial data, and practical guidance for patients and providers.
A clinician-level review of how tirzepatide (Mounjaro) affects sleep architecture, OSA severity, slow-wave sleep, and circadian biology, with primary-literature citations and a practical patient guide.
A guide to NMN and NR dosing considerations for adolescents aged 12, 17, covering the current evidence gap, safety signals, growth-velocity concerns, and what to discuss with your prescriber before use.
Missed your NMN or NR dose? Our MD-reviewed protocol explains exactly what to do, how NAD+ precursor kinetics affect the decision, and when doubling up is never appropriate.
No pediatric clinical trials exist for NMN or NR supplements in children under 12. Learn what the current evidence, FDA guidance, and clinical experts say about the risks of giving NAD precursors to young children.
Does NMN or NR affect appetite and food cravings? This MD-reviewed guide covers the mechanistic science, human trial data, and clinical context for nicotinamide mononucleotide and nicotinamide riboside on hunger regulation.
Yoshino 2021 RCT (N=25): NMN improved muscle insulin sensitivity in postmenopausal prediabetic women, GRADE Moderate. Other NMN/NR outcomes rate Low to Very Low.
A deep dive into the clinical evidence for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) effects on hair growth, skin aging, pigmentation, and barrier function, with real trial data and dosing guidance.
A clinician-level review of how NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) affect liver function, NAD+ metabolism, NAFLD/MASLD pathways, and safety signals from human trials.
A guide to NMN and NR microdosing protocols, covering dose ranges tested in human trials, pharmacokinetics, safety data, and what the science does and does not yet support.
Can stopping NMN or NR supplementation cause a rebound drop in NAD+ or reversal of benefits? A clinical review of the evidence, withdrawal physiology, and how to taper safely.
A clinician-level review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) as NAD+ precursors in kidney disease: mechanisms, human trial data, dosing, and real safety signals for renal patients.
A guide to how season, circadian biology, UV exposure, and metabolic shifts affect NMN and NR dosing strategies, with primary-literature citations throughout.
A deep dive into how NMN and NR supplementation affects sexual function, hormone balance, vascular health, and libido through NAD+ pathway biology. Includes clinical trial data, dosing guidance, and evidence-based expectations.
A clinical review of BPC-157 (pentadecapeptide) for wound healing. Covers off-label status, animal and human evidence, GRADE assessment, dosing considerations, and safety signals. prepared by the HealthRX.com Editorial Team.
A clinical review of CJC-1295 (modified GRF 1-29) for off-label fat loss use, covering mechanism, evidence quality, dosing protocols, risks, and how it compares to FDA-approved alternatives.
A guide to enclomiphene citrate for fertility, covering off-label status, evidence quality, dosing, and the monitoring protocols used in practice.
A clinical review of off-label enclomiphene citrate use in secondary hypogonadism, covering trial data, mechanism, dosing frameworks, side-effect profiles, and how it compares to TRT for men who want to preserve fertility.
A clinical deep-dive into off-label finasteride for female pattern hair loss (FPHL): evidence level, dosing protocols, contraindications, and how it compares to approved alternatives.
A detailed clinical review of off-label finasteride use in gender-affirming care for transgender women and nonbinary people, covering evidence quality, dosing, side effects, and how it compares to other antiandrogens.
A detailed evidence summary of copper tripeptide GHK-Cu as an off-label hair-growth agent, including mechanism, clinical data, dosing, and safety, prepared by the HealthRX.com Editorial Team.
A guide to GHK-Cu (copper tripeptide) for skin regeneration: what the clinical evidence shows, how it compares to FDA-approved alternatives, off-label status explained, and the monitoring framework clinicians recommend.
Separate ipamorelin hormone mechanisms from clinical fat-loss evidence, including what a postoperative bowel-recovery trial can and cannot show.
A evidence summary on using ipamorelin acetate off-label for longevity. Covers mechanism, clinical data quality, GRADE evidence levels, safety, and how it compares to approved GH therapies.
A clinical deep-dive into whether metformin works for non-alcoholic fatty liver disease (NAFLD): current evidence grade, off-label dosing protocols, and what the guidelines actually say.